Quantcast

Growth of Major Depressive Disorder Market in Current and Future Players in New Research Report Available at ReportsnReports.com

June 12, 2014

ReportsnReports.com adds “PharmaPoint Major Depressive Disorder – Current and Future Players” to its store. Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=288099.

Dallas, Texas (PRWEB) June 12, 2014

“PharmaPoint: Major Depressive Disorder – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market.

Companies Mentioned in this report are: Lundbeck, Forest Laboratories (Actavis), Eli Lilly, Pfizer, Otsuka Pharmaceutical, AstraZeneca, Takeda Pharmaceutical, Alkermes, Euthymics , ioscience, Naurex, e-Therapeutics.

Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=288099.

Scope

  •     Investigation of current and future market competition for Major Depressive Disorder.
  •     Competitor assessment
  •     Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  •     Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  •     Gain a high level view of the trends shaping and driving Major Depressive Disorder market.
  •     Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  •     Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  •     What’s the next big thing in the global Major Depressive Disorder market landscape? Identify, understand and capitalize

Complete Report Available at http://www.reportsnreports.com/reports/288099-pharmapoint-major-depressive-disorder-current-and-future-players.html.

1 Table of Contents

1 Table of Contents 7

1.1 List of Tables 9

1.2 List of Figures 10

2 Introduction 11

2.1 Catalyst 11

2.2 Related Reports 11

2.3 Upcoming Related Reports 13

3 Market Outlook 14

3.1 Global 14

3.1.1 Forecast 14

3.1.2 Drivers and Barriers – Global Issues 18

4 Current and Future Players 20

4.1 Overview 20

4.2 Trends in Corporate Strategy 23

4.3 Company Profiles 24

4.3.1 Lundbeck 24

4.3.2 Forest Laboratories (Actavis) 28

4.3.3 Eli Lilly 31

4.3.4 Pfizer 32

4.3.5 Otsuka Pharmaceutical 34

4.3.6 AstraZeneca 37

4.3.7 Takeda Pharmaceutical 38

4.3.8 Alkermes 40

4.3.9 Euthymics Bioscience 42

4.3.10 Naurex 44

4.3.11 e-Therapeutics 46

5 Appendix 49

5.1 Bibliography 49

5.2 Abbreviations 50

5.3 Methodology 52

5.4 Forecasting Methodology 52

5.4.1 Diagnosed MDD Patients 52

5.4.2 Percent of Drug-Treated Patients 52

5.4.3 General Pricing Assumptions 53

5.4.4 Generic Erosion 54

5.5 Physicians and Specialists Included in this Study 54

5.6 About the Authors 56

5.6.1 Analyst 56

5.6.2 Therapy Area Directors 56

5.6.3 Global Head of Healthcare 57

5.7 About GlobalData 58

5.8 Disclaimer 58

1.1 List of Tables

Table 1: Global Sales Forecasts ($) for MDD, 2013-2023 16

Table 2: MDD Market – Drivers and Barriers, 2013-2023 18

Table 3: Key Companies in the MDD Market in the 7MM and Australia, 2013 22

Table 4: Lundbeck’s MDD Portfolio Assessment, 2013 26

Table 5: Forest (Actavis)’s MDD Portfolio Assessment, 2013 29

Table 6: Eli Lilly’s MDD Portfolio Assessment, 2013 31

Table 7: Pfizer’s MDD Portfolio Assessment, 2013 33

Table 8: Otsuka’s MDD Portfolio Assessment, 2013 35

Table 9: AstraZeneca’s MDD Portfolio Assessment, 2013 37

Table 10: Takeda’s MDD Portfolio Assessment, 2013 39

Table 11: Alkermes’s MDD Portfolio Assessment, 2013 41

Table 12: Euthymics Bioscience’s MDD Portfolio Assessment, 2013 43

Table 13: Naurex’s MDD Portfolio Assessment, 2013 45

Table 14: e-Therapeutics’s MDD Portfolio Assessment, 2013 47

Table 15: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 55

1.2 List of Figures

Figure 1: Global Sales for MDD by Region, 2013-2023 17

Figure 2: Company Portfolio Gap Analysis in MDD, 2013-2023 23

Figure 3: Lundbeck SWOT Analysis in MDD, 2013-2023 27

Figure 4: Forest (Actavis) SWOT Analysis in MDD, 2013-2023 30

Figure 5: Eli Lilly SWOT Analysis in MDD, 2013-2023 32

Figure 6: Pfizer SWOT Analysis in MDD, 2013-2023 34

Figure 7: Otsuka SWOT Analysis in MDD, 2013-2023 36

Figure 8: AstraZeneca SWOT Analysis in MDD, 2013-2023 38

Figure 9: Takeda SWOT Analysis in MDD, 2013-2023 40

Figure 10: Alkermes SWOT Analysis in MDD, 2013-2023 42

Figure 11: Euthymics Bioscience SWOT Analysis in MDD, 2013-2023 44

Figure 12: Naurex SWOT Analysis in MDD, 2013-2023 46

Figure 13: e-Therapeutics SWOT Analysis in MDD, 2013-2023 48

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:

ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.

For the original version on PRWeb visit: http://www.prweb.com/releases/major-depressive-disorder/pharmapoint-market-growth/prweb11939128.htm


Source: prweb



comments powered by Disqus